Altamira Therapeutics Ltd.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsAltamira Therapeutics Ltd. is a Bermuda-domiciled pharmaceutical preparations company that filed its annual report on Form 20-F for fiscal year 2024 and trades on the OTCQB under the symbol CYTOF.
What they do
Altamira Therapeutics Ltd. is a pharmaceutical preparations company incorporated in Bermuda with its principal executive offices in Hamilton, Bermuda. The company holds trademarks including xPhore, OligoPhore, SemaPhore, and CycloPhore, while Bentrio is a registered trademark of Altamira Medica AG, an affiliate. The 20-F provides no further description of actual operations in the excerpts available.
Revenue drivers
- Not disclosed in excerpts — The available filing excerpts do not identify revenue-generating segments, products, or their relative sizes.
Recent performance
The most recent XBRL annual net income data available is for 2020, showing a net loss of $8.2 million, compared with a loss of $6.6 million in 2019 and $11.5 million in 2018. The latest balance sheet data available is as of December 31, 2020, with total liabilities of $840,677 and shareholder equity of $16.8 million. The 20-F covering fiscal year 2024 does not include revenue or earnings figures in the excerpts provided. The filing notes a one-for-twenty reverse share split effected on December 13, 2023, resulting in a par value of $0.002 per common share, with per-share amounts retrospectively adjusted.
Strategy
The filing excerpts do not disclose specific strategic initiatives, investments, or priorities beyond corporate and listing information. Altamira filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company effected a one-for-twenty reverse share split in December 2023, which it notes adjusted par value and share counts retrospectively. No forward-looking strategic statements from management are present in the available source material.
Risks
- Limited disclosure in available excerpts — The provided filing excerpts omit the business overview, MD&A, and risk factor sections, so company-specific risks cannot be assessed from this material.
- History of net losses — The most recent XBRL annual net income data, for 2020, shows a net loss of $8.2 million.
- Substantial shareholder equity decline unknown — The latest available balance sheet, dated December 31, 2020, shows shareholder equity of $16.8 million, and no more recent capital position is provided in the excerpts.
- OTCQB listing — The company's common shares trade on the OTCQB rather than a national securities exchange, as stated on the Form 20-F cover page.
Outlook
The filing excerpts do not contain management's outlook or forward-looking guidance. No statements about future products, financing, or operations are available in the source material.